| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 02.02.
| ThromboGenics Announces That the FDA Intends to Grant Ocriplasmin Priority Review | | 40 | PR Newswire |
| LEUVEN, Belgium, February 2, 2012 /PRNewswire/ --
Company to Re-Submit Ocriplasmin BLA to Meet Priority Review Timelines
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused...
Mehr lesen zu:
ThromboGenics Announces That the FDA Intends to Grant Ocriplasmin Priority Review | |
| 23.12.
| ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA | | 45 | PR Newswire |
| LEUVEN, Belgium, December 23, 2011 /PRNewswire/ --
If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole
ThromboGenics...
Mehr lesen zu:
ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA | |
| 16.12.
| ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule | | 3 | Business Wire |
| ThromboGenics NV (Euronext Brussels: THR) and co-development partner
BioInvent International (OMXS: BINV) announce today that they have
completed the enrolment of a 632-patient...
Mehr lesen zu:
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule | |
| 16.12.
| ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule | | 4 | PR Newswire |
| LEUVEN, Belgium and LUND, Sweden, December 16, 2011 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they...
Mehr lesen zu:
ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule | |
| 20.10.
| ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day | | 26 | PR Newswire |
| LEUVEN, Belgium, October 20, 2011 /PRNewswire/ --
Leading retinal specialist also invited to present ocriplasmin responder analysis forthe treatment of macular holes at Best of the Posterior...
Mehr lesen zu:
ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day | |
| 19.10.
| ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin | | 23 | PR Newswire |
| LEUVEN, Belgium, October 19, 2011 /PRNewswire/ --
If Approved, Ocriplasmin Will be the First Pharmacological Treatment for Symptomatic Vitreomacular Adhesion (VMA) Including Macular Hole
ThromboGenics...
Mehr lesen zu:
ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin | |
| 22.08.
| ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS) | | 54 | PR Newswire |
| LEUVEN, Belgium, August 22, 2011 /PRNewswire/ --
New data presented by leading retinal specialists Dr Pravin U.Dugel,MD(Phoenix,AZ) and Dr Peter K. Kaiser, MD (Cleveland,OH)
ThromboGenics...
Mehr lesen zu:
ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS) | |
